1256386-96-5

Upstream product

• 1256386-95-4 (S,S)-4-(2-(4-bromophenyl)-2-oxoethylcarbamoyl)-3-(2-methoxycarbonylamino-3-methylbutyryl)imidazolidine-1-carboxlic acid tert-butyl ester 
• 1256386-93-2 (S,S)-1-benzyl-3-(2-methoxycarbonylamino-3-methylbutyryl)imidazolidine-4-carboxlic acid methyl ester 
• 1256386-94-3 (S,S)-3-(2-methoxycarbonylamino-3-methylbutyryl)imidazolidine-1,4-dicarboxlic acid 1-tert-butyl ester 4-methyl ester 
• 1256386-24-9 (S,S)-4-(4-bromophenyl)-3'-(2-methoxycarbonylamino-3-methylbutyryl)-2',3',4',5'-tetrahydro-1H-[2,4']biimidazolyl-1'-carboxlic acid tert-butyl ester 
• 1228553-33-0 [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidine-1-carbonyl)propyl]carbamic acid methyl ester 

Relevant academic research and scientific papers

ANTIVIRAL COMPOUNDS HIGHLY EFFECTIVE AS HCV-NS5A INHIBITOR

Provided are compounds antiviral compounds represented by formula Ia and Ib: that are highly potent as HCV NS5A inhibitors, where the structural variables are as defined herein. These compounds are useful in, for example, inhibiting Hepatitis C virus and treating Hepatitis C virus infections.

ANTIVIRAL COMPOUNDS

The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.